Novo Nordisk will present new data on semaglutide for metabolic dysfunction-associated steatohepatitis (MASH) at the European Association for the Study of the Liver (EASL) Annual Congress in late May. MASH is a progressive liver disease that affects an estimated 250 million people globally.
The presentation features results from the ESSENCE clinical trial. This data confirms a favorable hepatic safety profile for semaglutide in MASH patients.
Subgroup analyses demonstrate benefits across a diverse spectrum of patients. These findings address a critical need in a market with historically limited and poorly tolerated treatment options. The results highlight a potential major new indication for Novo Nordisk’s primary drug.